Regulus Therapeutics, Inc.

Regulus Therapeutics, Inc.

Regulus Therapeutics, Inc.

Overview
Date Founded

2007

Headquarters

10628 SCIENCE CENTER DRIVE SUITE 100 SAN DIEGO CA 92121

Type of Company

Public

Employees (Worldwide)

24

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.

Contact Data
Trying to get in touch with decision makers at Regulus Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial & Accounting Officer

Secretary, Senior Vice President & General Counsel

Senior Vice President, Human Capital

Vice President, Pharmaceutical Development

Vice President, Pharmaceutical Development

Leader

Director

Associate Director, CMC Analytical Development

Corporate Secretary

Board of Directors

Co-Founder at Exelixis, Inc.

Director at Grail, Inc.

President Emeritus at California Institute of Technology

Venture Advisor at NEA Management Co. LLC

Founder at PWH Advisors

Co-Founder at Blackthorn Therapeutics, Inc.

President & Chief Executive Officer at Regulus Therapeutics, Inc.

Partner at Sarissa Capital Management LP

Treasurers at University of San Diego - School of Business Administration

Paths to Regulus Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Regulus Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Founded in 1998, DRW Securities LLC is a broker/dealer located in Chicago. The firm is a subsidiary of DRW Holdings LLC. The firm is indirectly owned by DRW Trading Group, a principal trading firm formed in 1992, and Donald R. Wilson. DRW Trading Group's trading spans a diverse set of asset classes and instruments, both domestically and internationally. Trading is diversified as to strategies, asset classes, instruments and geographical presence. DRW Trading Group focuses on finding liquid, centrally-cleared futures and futures options, thus eliminating the counterparty exposure associated with OTC/bilateral trading. DRW trading Group is an active participant on exchanges in the US, and Europe, including the Chicago Mercantile Exchange, the Chicago Board of Trade, the New York Mercantile Exchange, the Intercontinental Exchange, Eurex and LIFFE.

Details Hidden

Founded in 1998, DRW Securities LLC is a broker/dealer located in Chicago. The firm is a subsidiary of DRW Holdings LLC. The firm is indirectly owned by DRW Trading Group, a principal trading firm formed in 1992, and Donald R. Wilson. DRW Trading Group's trading spans a diverse set of asset classes and instruments, both domestically and internationally. Trading is diversified as to strategies, asset classes, instruments and geographical presence. DRW Trading Group focuses on finding liquid, centrally-cleared futures and futures options, thus eliminating the counterparty exposure associated with OTC/bilateral trading. DRW trading Group is an active participant on exchanges in the US, and Europe, including the Chicago Mercantile Exchange, the Chicago Board of Trade, the New York Mercantile Exchange, the Intercontinental Exchange, Eurex and LIFFE.

Recent Transactions
Details Hidden

Regulus Therapeutics, Inc. issued USD Common Stock

Details Hidden

Regulus Therapeutics, Inc. issued Common Stock

Details Hidden

Regulus Therapeutics, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onRegulus Therapeutics, Inc. issued Common Stock

Underwriter

Advised onRegulus Therapeutics, Inc. issued Common Stock

Underwriter

Advised onRegulus Therapeutics, Inc. issued Common Stock

Head of Business & Technology Practice Group

Advised onRegulus Therapeutics, Inc. issued Common Stock

Managing Director

Advised onRegulus Therapeutics, Inc. issued Common Stock

Professional

Advised onRegulus Therapeutics, Inc. issued Common Stock

Advisors & Consultants
Legal Advisor

Partner, San Diego at Cooley LLP

Advisor

President Emeritus at California Institute of Technology

Advisor

Co-Founder at Alnylam Pharmaceuticals, Inc.

Clients

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Key Stats and Financials As of 2018
Market Capitalization
$14.4M
Total Enterprise Value
$10.8M
Earnings Per Share
$-5.59
Revenue
$72K
Net Profit
$-48.7M
EBITDA
$-43.7M
EBITDAMargin
-60.7K%
Total Debt
$16.6M
Total Equity
$-5.85M
Enterprise Value Sales
149.35x
TEVNet Income
-0.22x
Debt TEV
1.54x
Three Year Compounded Annual Growth Rate Of Revenue
-84.86%
Five Year Compounded Annual Growth Rate Of Revenue
-67.4%
Non-Profit Donations & Grants
Investors
Details Hidden

Sanofi-Aventis U.S. LLC offers pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ.

Details Hidden

Oxford Finance Corporation operates as a specialty financial services company. It offers senior secured, asset-based, equipment, and working capital loans. The company primarily serves public and private life science companies. Oxford Finance Corporation was founded in 2002 and is headquartered in Alexandria, Virginia with additional offices in Massachusetts and California. Oxford Finance Corporation operates as a subsidiary of Sumitomo Corporation of America

Suppliers
Alnylam Pharmaceuticals, Inc. Medical Support Services | Cambridge, MA

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Stanford University Biotechnology | Palo Alto, CA

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to big challenges and to preparing students for leadership in a complex world.

Max Planck Society Publishing | Munich, BV

The Max Planck Society for the Advancement of Science (German: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.; abbreviated MPG) is a non-governmental and non-profit association of German research institutes publicly funded by the federal and the 16 state governments of Germany. It is named in honor of its former president, theoretical physicist Max Planck. The 82 research institutes of the Max Planck Society (as 2013) conduct basic research in the interest of the general public in the natural sciences, life sciences, social sciences, and the arts and humanities. They have a total staff of approximately 17,000 permanent employees, including 5,470 scientists, plus around 4,500 non-tenured scientists and guests. The Max Planck Society has a world-leading reputation as a science & technology research organization, with 32 Nobel Prizes awarded to their scientists, and are generally regarded as the foremost basic research organization in Europe and the world.

Competitors
Roche Holding AG Pharmaceuticals - Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Regulus Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Regulus Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Regulus Therapeutics, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/regulus-therapeutics-inc-963077
  • https://relationshipscience.com/organization/regulus-therapeutics-inc-963077